Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders. It has seven programs in its pipeline, but only two are in clinical trials. Dyne focuses on treating ...

Jan 3 (Reuters) - Shares of drug developer Dyne Therapeutics (DYN.O), opens new tab jumped 18% on Wednesday after its experimental therapy for a muscle-wasting disorder called Duchenne muscular ...

Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy ...

Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...

Dyne Therapeutics (DYN) has been appearing on more watchlists lately, and it is easy to see why investors might be pausing to assess their next move. With so much energy around biotech innovation, any ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne Therapeutics announced that its investigational therapy, called DYNE-251, ...

Shares of Dyne Therapeutics (NASDAQ:DYN) dropped ~21% in the premarket on Tuesday after the company indicated a delay in filing for U.S. approval of DYNE-101, an experimental therapy for a rare muscle ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.